All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only

Search results for "CAS number"

Found 11 products

11 results

Sort by:

Epithalon (Epitalon)

Epithalon (Epitalon)

Pineal Tetrapeptide: 4-amino acid sequence (AEDG), ≥99% purity, naturally occurring compound
Telomerase Activation: hTERT upregulation, telomere elongation, dual pathway mechanism
Geroprotective Research: Pineal melatonin biosynthesis, circadian rhythm regulation, antioxidant defense

$32.00

GHK-Cu 50mg Copper Peptide

GHK-Cu 50mg Copper Peptide

GHK-Cuis a research peptide composed of the tripeptide sequence Gly-His-Lys bound to copper(II) ions, forming a biologically active peptide–metal complex studied for its role in extracellular matrix modulation and cellular signaling
Preclinical research indicates that GHK-Cu regulates collagen production, gene expression, and enzymatic antioxidant pathways through copper-mediated redox mechanisms
It serves as a model compound for investigating peptide-driven tissue remodeling, metalloprotein r

$99.00

L-Glutathione 600mg

L-Glutathione 600mg

Master Antioxidant Tripeptide: L-γ-Glu-L-Cys-Gly sequence, ≥98% purity
Cellular Redox Homeostasis: Primary intracellular thiol buffer (0.5-10 mM)
Phase II Detoxification: GST-mediated conjugation and xenobiotic metabolism studies

$60.00

GLOW BLEND (50mg)

GLOW BLEND (50mg)

Triple-Peptide Blend: BPC-157 + TB-500 + GHK-Cu for comprehensive tissue regeneration
Multi-Phase Coverage: Inflammation, angiogenesis, cell migration, and matrix remodeling
Research Formulation: 50mg total, ≥98% purity per component, lyophilized powder

$97.00

KLOW (80mg)

KLOW (80mg)

Quad-Peptide Blend: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total)
Enhanced Anti-Inflammatory: KPV addition for NF-κB pathway inhibition and cytokine control
Comprehensive Regeneration: Cytoprotection, angiogenesis, collagen synthesis, and inflammation modulation

$110.00

KLOW

KLOW

Advanced Quad-Peptide Research Formulation: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total), extends GLOW Blend with KPV for enhanced inflammation modulation
Comprehensive Repair Cascade: BPC-157 (cytoprotection, VEGFR2 activation), TB-500 (cell migration, angiogenesis), GHK-Cu (collagen synthesis, 4,000+ gene modulation), KPV (NF-κB inhibition, anti-inflammatory signaling)
KPV Anti-Inflammatory Mechanism: C-terminal tripeptide of α-MSH, NF-κB pathway inhibition, TNF-α/IL-1β/IL-6 suppression, NO melanotropic effects (lacks melanocortin core sequence required for MC1R activation)

$110.00

Oxytocin 10mg (6000 IU)

Oxytocin 10mg (6000 IU)

Cyclic nonapeptide hormone with characteristic Cys1-Cys6 disulfide bridge, synthesized by Nobel laureate Vincent du Vigneaud (1954)
OXTR agonist activating Gq/11-PLC-IP3/DAG cascade; modulates social cognition, stress axis, metabolism, and cardiovascular function
Validated in ~25,000 publications spanning social neuroscience, reproductive physiology, psychiatry, metabolic medicine, and cardiology

$19.00

Melanotan-2 (10mg)

Melanotan-2 (10mg)

Cyclic heptapeptide analog of alpha-MSH with 100-1000x greater potency at melanocortin receptors
Pan-agonist of MC1R, MC3R, MC4R, MC5R with extended half-life (~33 hours vs. minutes for native alpha-MSH)
Validated in 400+ publications across pigmentation, energy homeostasis, sexual function, neuroprotection, and cardiovascular research

$35.00

B-12 (10ml)

B-12 (10ml)

Essential Cobalt-Containing Vitamin: Cyanocobalamin (C₆₃H₈₈CoN₁₄O₁₄P), 1000 mcg/mL injectable solution
Methylation Pathway Cofactor: Critical for methionine synthase and methylmalonyl-CoA mutase enzymatic reactions
Neurological Research Tool: Supports studies in myelin synthesis, DNA methylation, and neuroprotection

$59.00

PT-141 10mg

PT-141 10mg

FDA-Approved Melanocortin Agonist: Cyclic heptapeptide MC3R/MC4R agonist, approved June 2019 (Vyleesi) for premenopausal HSDD, 100+ publications, first melanocortin therapeutic for sexual function
CNS Mechanism: Crosses blood-brain barrier, activates hypothalamic MC4R in mPOA triggering dopamine release, melanocortin-dopamine integration, mesolimbic reward pathway modulation
Clinical Development: 43 completed trials with 3,500+ subjects, Phase 3 RECONNECT (n=1,267) showed +0.35 desire improvement, 58% vs 36% responder rates, well-characterized safety profile

$33.25

Thymosin Alpha-1

Thymosin Alpha-1

28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

$49.00